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Abstract
Background: About 20 % of hereditary breast cancers are caused by mutations in BRCA1 and BRCA2 genes. Since
BRCA1 and BRCA2 mutations may be spread throughout the gene, genetic testing is usually performed by direct
sequencing of entire coding regions. In some populations, especially if relatively isolated, a few number of recurrent
mutations is reported, sometimes caused by founder effect.
Methods: BRCA1 and BRCA2 screening for mutations was carried out on 1114 breast and/or ovarian cancer patients
complying with the eligibility criteria for BRCA testing. Haplotype analysis was performed on the probands carrying
recurrent mutations and their relatives, using two sets of microsatellite markers covering the BRCA1 (D17S588,
D17S806, D17S902, D17S1325, D17S855, D17S1328, D17S800, and D17S250) and BRCA2 (D13S220, D13S267,
D13S171, D13S1701, D13S1698, D13S260, D13S290, D13S1246) loci. The DMLE + 2.2 software was used to estimate
the age of BRCA1 c.676delT and BRCA2 c.7806-2A > G. A multiplex PCR and two different primer extension assays
were optimized and used for genotyping the recurrent mutations of the two genes.
Results: In the time frame of almost 20 years of genetic testing, we have found that five BRCA1 and three BRCA2
mutations are recurrent in a substantial subset of carriers from North-East Italy and neighboring Istria, where they
represent more than 50 % of all mutations. Microsatellite analyses identified a common haplotype of different
length for each mutation. Age estimation of BRCA1 c.676delT and BRCA2 c.7806-2A > G mutations revealed that
they arose in the Friuli Venezia Giulia area about 86 and 94 generations ago, respectively. Suggestion of an
association between BRCA2 c.7806-2A > G and risk of breast cancer in males has emerged. Finally, we developed a
simple and efficient pre-screeening test, performing an in-house primer extension SNaPshot® assay for the rapid
identification of the eight recurrent mutations.
Conclusions: Proofs of common ancestry has been obtained for the eight recurrent mutations. The observed
genotype-phenotype correlation and the proposed rapid mutation detection strategy could improve the clinical
management of breast and ovarian patients in North-East of Italy and neighboring geographic areas.
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Background
About 3-8 % of breast and ovarian cancers are hereditary
and are due to constitutional mutations in cancer pre-
disposing genes. Mutations of the BRCA1 (OMIM
113705) and BRCA2 (OMIM 600185) genes contribute
to a significant number of hereditary cases and are
inherited in a dominant autosomic manner with high
penetrance [1].
Women carrying BRCA1 mutations are particularly at
risk of developing breast cancer at very early age and
ovarian cancer during their life, while women carrying a
BRCA2 mutation tend to develop breast cancer later in
their life and have a significantly lower susceptibility to
ovarian cancer [2].
Thousands of different mutations have been found in
both genes and are dispersed throughout the coding se-
quences, but the mutation spectra and proportion of
high-risk mutated families varies widely among different
populations. Some populations present a wide spectrum
of different mutations, while particular ethnic groups
present high frequency of a single or a few recurrent
mutations, usually due to a founder effect [3, 4].
Among the several well established founder mutations,
the 3 mutations of the Ashkenazi Jews (AJ), i.e. BRCA1
c.68_69delAG and c.5266dupC, BRCA2 c.5946delT, are
worthy of particular mention because overall they ac-
count for 6.7-11.7 % of all breast cancer patients and
59 % of patients from high-risk breast cancer families in
this population [3]. Among the approximate 30.000 en-
tries of the BIC database [5], these 3 mutations are at
the head of both “top 20 mutation frequencies lists”.
However, this reflects in part their high recurrence also
in non-Jews Caucasian populations, because these muta-
tions likely existed before the Jewish diaspora.
Another famous and well-studied founder mutation is
the BRCA2 c.771del5, that is identifiable in approximately
8 % of both breast cancer and ovarian cancer Icelandic
cases [6]. However, hundreds of recurrent and/or founder
mutations have been reported in the last 15 years by sev-
eral papers variably describing mutation types, frequency
and distribution, haplotype sharing, common ancestor
and mutation age, clinical phenotype and so on [3, 7, 8].
Several recurrent/founder mutations have been already re-
ported also in Italy, each one confined within a limited re-
gional geographic area. The most significant examples are
BRCA1 c.1378dupA and c.3228_3229delAG in Tuscany
[9, 10], BRCA1 c.4964del19 in Calabria and Sicily [11],
BRCA1 p.Val1688del in Veneto [12], BRCA2 c.8537delAG
and c.3723del3insAT in Sardinia [13, 14], and more re-
cently, BRCA1 p.Cys64Arg in the Lombardy region [15].
The present study focus on the BRCA1 and BRCA2
mutations that were observed multiple times among the
patients of the North-East of Italy undergoing genetic
testing for hereditary breast/ovarian cancer. Haplotype
sharing and age calculation analyses are presented along
with a multiplex genotyping test that has been developed
for improving our screening strategy, allowing rapid




In the time frame of 19 years (1996–2014), 1114 breast
and/or ovarian cancer patients complying with the eligi-
bility criteria for BRCA testing [16], were screened for
BRCA1 or BRCA2 mutations. The updated criteria in
use at the Centro di Riferimento Oncologico (CRO, Na-
tional Cancer Institute, Aviano) were (a) three or more
cases of breast and/or ovarian cancer at any age, with
one case being a first-degree relative of the other two;
(b) two first-degree relatives with breast cancer diag-
nosed before 50 years of age or at any age but with one
case of bilateral breast cancer; (c) two first-degree rela-
tives with ovarian cancer at any age or one ovarian can-
cer at any age and one breast cancer before the age of
50; and (d) one case of breast cancer before the age of
36 or breast cancer in male or breast and ovarian cancer
in the same woman.
All patients were recruited in the setting of genetic
counseling in Centers of the region Friuli Venezia Giulia
(FVG), namely at CRO in Aviano (~65 %) and at the In-
stitutes of Medical Genetics in Udine (~30 %) and Burlo
Garofalo in Trieste (~5 %). Detailed family histories, in-
cluding information on geographic origins, were ob-
tained for all patients. Genealogic investigations did not
reveal any relationship between individuals from differ-
ent families. Informed consent for genetic testing and re-
search was obtained from all participants. The genetic
testing protocol and use of DNA samples for research
purposes was evaluated and approved by the Local Inde-
pendent Ethical Committee (CRO-15-1997).
Genomic DNA was purified from blood samples of
each proband. In the majority of samples screening for
mutations in the BRCA1/BRCA2 genes was carried out
by a combination of Denaturing High Performance Li-
quid Cromatography (DHPLC), direct DNA Sanger-
sequencing and Multiplex-Ligation Dependent Probe
Amplification (MLPA) techniques; Single Strand Con-
formation Polymorphism and Protein Truncation Test
had been used instead of DHPLC and Sequencing for
testing the first 300 cases, only.
Overall, the study was carried out on 62 apparently
unrelated families carrying one of the 8 most recur-
rent mutations listed in Table 1 (39 BRCA1, 23
BRCA2). Besides the 62 mutated probands, a total of
120 relatives were also included in the study (54 car-
riers and 62 non-carriers).
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Ninety-one healthy blood donors, all born and resident
in the North-Eastern Italy, were investigated to estimate
allele frequencies and control haplotypes in the general
population.
Microsatellite analysis
Haplotype analysis was performed using two sets of 8
microsatellite markers covering the BRCA1 and BRCA2
loci and spanning regions of approximately 11 Mb/
8.7 cM and 4.1 Mb/7.0 cM, respectively. The following
microsatellites, listed in order from telomere to centro-
mere, were analyzed in BRCA1-mutated samples:
D17S588, D17S806, D17S902, D17S1325, D17S855,
D17S1328, D17S800, and D17S250. The microsatellites
investigated in the BRCA2-mutated samples were:
D13S220, D13S267, D13S171, D13S1701, D13S1698,
D13S260, D13S290, D13S1246 (Fig. 1). PCR primer se-
quences were obtained from the Probe NCBI database
[17] or designed using Primer Blast software [18]. Primer
sequences and PCR conditions are available on request.
PCR product size was evaluated by capillary electrophor-
esis on an ABI PRISM 3130 Sequencer using GeneMap-
per 4.0 software (Applied Biosystems/Life technologies,
Foster City, CA, USA).
The distributions of allelic and haplotype frequencies
in normal and mutated chromosomes were compared by
Fisher’s exact tests; P < 0.05 and P < 0.01 were considered
as a cut-off for statistical significance.
Haplotyping and estimate of mutation age
Haplotypes were manually constructed for each muta-
tion to minimize the number of recombinations. The
cut off used for defining a founder effect was the associ-
ation of the mutated BRCA1 or BRCA2 allele with a core
haplotype spanning a minimum of 2 microsatellite
markers.
The DMLE + 2.2 software developed by Reeve and
Rannala [19] was used to estimate the age of BRCA1
Table 1 List of the most common BRCA mutations and their recurrence in the CRO Aviano database and BIC database
GENE MUTATIONa BIC database CRO database CRO haplotype study
BRCA1 c.116G > A (p.Cys39Tyr) 5x 11x 7
BRCA1 c.181T > G (p.Cys61Gly) 239x 13x 7
BRCA1 c.676delT (p.Cys226Valfs*8) 16x 10x 9
BRCA1 c.1687C > T (p.Gln536*) 94x 12x 7
BRCA1 c.5266dupC (p.Gln1756Profs*74) 1088x 15x 9
BRCA2 c.5682C > G (p.Tyr1894*) 62x 7x 5
BRCA2 c.7806-2A > G (p.Ala2603_Arg2659del) 5x 19x 13
BRCA2 c.8878C > T (p.Gln2960*) 10x 6x 5
aThe mutations are defined according to the Human Genome Variation Society guidelines; the symbol "*" indicates a predicted stop codon [46]
Fig. 1 Schematic representation of (a) chromosome 17 and (b) chromosome 13. Relative positions of BRCA1 and BRCA2 genes and the flanking
microsatellites are shown
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c.676delT and BRCA2 c.7806-2A > G, as previously de-
scribed [20, 21]. All the families with these two muta-
tions clustered in the FVG.
The program, freely available online [22], uses a Bayes-
ian approach to compare differences in linkage disequi-
librium between the mutation and flanking markers in
DNA samples from mutation carriers and controls. The
software generates the marginal posterior probability
density of mutation age based the following parameters:
a) observed haplotypes or genotypes in normal and af-
fected chromosomes; b) map distances between markers
and mutation site; c) population growth rates and d) an
estimated proportion of the mutation bearing chromo-
somes sampled.
Map distances were estimated on the basis of positions
and physical distances given by the genetic map Hap-
Map Phase II [23].
The population growth rate (genr) was estimated as re-
ported previously [20]. The total population of the FVG
region currently comprises 1,229,363 people [24]. His-
torical and demographic data indicate that about
160,000 people lived in this area in year 1200 [25]. Ac-
cordingly, the average genr of this population was esti-
mated to be 0.063 from 1200 to the present time,
assuming 25 years/generation.
Taken for granted that the prevalence of BRCA1 and
BRCA2 carriers is about 1:1000 each in the general
population [26], three separate analyses were then per-
formed, each using a different estimate for the propor-
tion of sampled mutation-carrying chromosomes: 0.015,
0.01, and 0.005 [15].
Primer extension SNaPshot® assay
Two different multiplex primer extension assays were
optimized and used for genotyping the 8 recurrent mu-
tations of the two genes. We used the SNaPshot® label-
ing chemistry (Applied Biosystem/Life technologies) that
relies on single-base extension and termination using
custom primers located upstream or downstream of the
mutation site.
First of all, a single octaplex PCR was carried out for
simultaneously amplify exons 3, 5, 20 and two portions
of exon 11 of the BRCA1 gene, plus exons 17, 22 and a
portion of exon 11 of the BRCA2 gene. The primers
adopted for this test were the same we normally used
for complete gene mutational screenings by DHPLC
and/or direct sequencing (available upon request).
Multiplex PCRs were performed with 0.1–0.4pmol of
each primer and 2X QIAGEN Multiplex PCR Master
Mix (Qiagen, Inc., Frederick, Maryland, USA) in a vol-
ume of 20 μl, according to manufacturer instructions
and using the following conditions: denaturation at 95 °
C for 15 min, followed by 40 cycles of 95 °C for 30 sec,
56 °C for 90 sec and 72 °C for 90 sec, and a final
extension step of 72 °C for 10 min. When all expected
PCR products and their sizes had been confirmed by
electrophoresis on a 3 % agarose gel, the reaction was
purified with ExoSAP (Exonuclease I and Shrimp Alka-
line Phosphatase, GE-Healthcare, Buckinghamshire, UK)
15 min at 37 °C followed by 15 min at 75 °C) to remove
excess dNTP and primers.
Multiplex nucleotide primer extension was carried out
in a final volume of 10 μl containing 3 μl of purified
PCR product, 0.2pM of each internal primer, 1 μl of 5X
Sequencing Buffer (Applied Biosystem/Life technolo-
gies), and 2.5 μl of SNaPshot® MultiplexReady Reaction
Mix (Applied Biosystems/Life technologies). Internal
primers were constructed to have Tm of approximately
60 °C and sizes between 20 and 27 nucleotides, but with
added poly(A) tails of different lengths to their 5' end
(Table 2). The BRCA1 primer pool comprised 5 primers,
while the BRCA2 primer pool included 3 primers.
The reaction was performed as recommended by the
manufacturer in a thermal cycler (25 cycles), then
treated by SAP (GE-Healthcare) 60 min at 37 °C and
15 min at 75 °C, run on the ABI PRISM 3130 Genetic
Analyzer and evaluated with GeneMapper software (Ap-
plied Biosystems/Life technologies).
Results
Frequency of BRCA recurrent mutations
Overall, following the mutational screening of 1114 eli-
gible probands, different BRCA1/BRCA2 deleterious
mutations were identified in 221 unrelated patients
(18.9 %). Thirty-five BRCA1 and 26 BRCA2 mutations
were unique, while 15 BRCA1 and 19 BRCA2 mutations
were recurrent in 2–18 families. On the whole, 160 out
of 1114 probands had a recurrent mutation.
We focused our attention to the 8 sequence variants
listed in Table 1, which had a recurrence of at least 6
times. Overall, these mutations were responsible for the
increased genetic risk in 93 unrelated probands/families,
which represented 42 % (93/221) of the total number of
cases with identified BRCA deleterious mutations in our
Center. One hundred and fourty-seven of 221 mutated
probands were born and resident in North-Eastern Italy,
specifically in different provinces of the FVG and Veneto
regions, or came from the neighboring Istria, a peninsula
previously Italian but split between Italy, Croatia and
Slovenia after the second world war (Fig. 2). Among this
subgroup, 80 families carried the 8 common variants.
Therefore, by restricting the evaluation to the patients
sharing this common geographic origin, the frequency of
the 8 recurrent mutations increased to 54 % (80/147).
Haplotype analysis and age estimation
To investigate a possible founder effect, allele and haplo-
type analyses were performed on 62 families carrying
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one of the 8 recurrent BRCA mutations. For this analysis
only families enrolled within the end of year 2011 were
selected (Table 1). In details, 100 individuals (39 pro-
bands and 61 relatives) from 39 families segregating 5
recurrent BRCA1 mutations, 78 individuals (23 probands
and 55 relatives) from 23 families segregating 3 recur-
rent BRCA2 mutations and the 91 control subjects were
investigated.
The D17S1325 marker was not informative and was
then excluded from the analysis.
The most common allele among the probands was
considered for each microsatellite marker flanking the
BRCA1 and BRCA2 loci, and its frequency was com-
pared between cases and controls. Statistically significant
differences in allele frequencies between mutated pro-
bands and normal controls were observed for the
markers located closer to each BRCA1 and BRCA2 vari-
ant (Tables 3, 4). In particular, D17S902 and D17S855
showed significant differences for all five BRCA1
mutations, and D13S1698 for all three BRCA2 mutations
(p < 0.05).
For the haplotype analysis, evaluation of the inform-
ative microsatellites was performed on probands and,
when possible, on additional family members. Sharing of
common haplotypes of different length was evident, sug-
gesting a founder effect for all examined mutations. In-
deed, core haplotypes extending over 2 to 5 markers
were associated with each mutation, since they were
present in at least 50 % of mutated chromosomes, but
were absent or rare in the control chromosomes (Fig. 3).
The BRCA1 c.676delT and the BRCA2 c.7806-2A > G
were further investigated. All the 7 informative families
with c.676delT shared a common haplotype at loci
D17S902, D17S855 and D17S1328 (149-149-247) span-
ning a region of approximately 487 kb (0.14 cM) [23]
(Table 5). The same haplotype was compatible with the
observed genotypes of two additional single individuals
for which the phase could not be explored, due to the
Table 2 Internal SNaPshot® primers for the analysis of 8 BRCA recurrent mutations
GENE Mutation Primer name Sequence Orientationa Size ddNTP wt/mut Signal colour
BRCA1 c.116G > A 1snap116-S AAAAAAAAACAAGGAACCTGTCTCCACAAAGT S 32 G/A Blue/Green
BRCA1 c.181T > G 1snap181-S AACAGAAGAAAGGGCCTTCACAG S 23 T/G Red/Blue
BRCA1 c.676delT 1snap676-AS AAAAAAAAAGTTACATCCGTCTCAGAAAATTCACA AS 35 A/G Green/Blue
BRCA1 c.1687C > T 1snap1687-AS AAAAAAAAAAAAACTATTGGGTTAGGATTTTTCTCATTCT AS 40 G/A Blue/Green
BRCA1 c.5266dupC 1snap5266-S AAAGCGAGCAAGAGAATCCC S 20 A/C Green/Black
BRCA2 c.5682C > G 2snap5682-S AAAAAAAACGAAAATTATGGCAGGTTGTTA S 30 C/G Black/Blue
BRCA2 c.7806-2A > G 2snap7806-AS TGGAGTGTCACACAGAGCCC AS 20 T/C Red/Black
BRCA2 c.8878C > T 2snap8878-AS GTTGTGACATCCCTTGATAAACCTT AS 25 G/A Blue/Green
aS sense, AS antisense
Fig. 2 Map of North-East Italy and Istria. In grey, Italian official regions FVG and Veneto, and geographical region of Istria (Italy, Slovenia
and Croatia)
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lack of additional family members. Furthermore, this
common haplotype was not found in 94 % of control
chromosomes, but could not be excluded in the
remaining 6 % (data not shown).
Six informative families with c.7806-2A > G shared an
identical haplotype at loci D13S267, D13S171 and
D13S1701 (144–230–299) spanning a region of approxi-
mately 1120 kb (1.58 cM) [23] (Table 6). The same
haplotype combination was still likely in the 7 remaining
families/individuals. Conversely, this haplotype could be
excluded in 88 % of the tested controls (data not shown).
In addition, segregation analysis of the nearest c.7806-14
C/T polymorphism (rs9534262) demonstrated that all 11
informative mutant alleles also shared nucleotide T at
this position (Table 6), despite its reported population
frequency of 0.453 [27].
All 22 families with these two latter mutations clus-
tered in the FVG region (provinces of Pordenone, Udine,
Trieste and Gorizia).
Given the three different proportions of sampled
mutation-carrying chromosomes (0.005, 0.01, 0.015) the
mutation age estimates for BRCA1 c.676delT were ap-
proximately 91 generations (standard deviation 22, 95 %
46–126), 85 generations (standard deviation 22, 95 %
43–120), 83 generations (standard deviation 21, 95 %
40–116) (Fig. 4a). Considering a generation time of
25 years the corresponding ages in years were 2275,
2125, 2075. For BRCA2 c.7806-2A > G the mutation ages
were approximately 102 generations (standard deviation
22, 95 % 68–137), 89 generations (standard deviation 18,
95 % 61–117), 90 generations (standard deviation 21,
95 % 59–120) (Fig. 4b). The age estimates are 2550 years,
2225 years, and 2250 years.
Genotype-phenotype correlations
Data on sex, tumor, age and family history of all the
cases of our database with the BRCA1 c.676delT and
BRCA2 c.7806-2A > G are summarized in Table 7.
Table 3 Frequencies of the most common microsatellite alleles of the BRCA1 region in mutated probands and controls
Markersa
D17S588 D17S806 D17S902 D17S855 D17S1328 D17S800 D17S250
48215496 45811789 41647103 41204744 41159779 39056258 37152091
136–160 136–182 137–173 143–157 247–267 166–178 145–163
c.116G > A Allelesb 156 170 149 149 247 170 149
Cases (14)c 4 (0.29) 6 (0.43) 6 (0.43) 8 (0.57) 11 (0.79) 5 (0.36) 5 (0.36)
Controls (140–180)c 52 (0.37) 30 (0.17) 32 (0.18) 28 (0.16) 146 (0.81) 80 (0.45) 45 (0.26)
P valued n.s. <0.05 <0.05 <0.01 n.s. n.s. n.s.
c.181T > G Allelesb 148;156e 174 141 153 247 166 147
Cases (14)c 4 (0.29);4 (0.29) 3 (0.21) 10 (0.71) 9 (0.64) 14 (1.0) 6 (0.43) 4 (0.29)
Controls (140–180)c 33 (0.24);52 (0.37) 16 (0.09) 24(0.13) 24 (0.13) 146 (0.81) 16 (0.09) 23 (0.13)
P valued n.s. n.s. <0.01 <0.01 n.s. <0.01 n.s.
c.676delT Allelesb 154 170 149 149 247 174 149
Cases (18)c 10 (0.56) 10 (0.56) 10 (0.56) 9 (0.50) 16 (0.89) 10 (0.56) 5 (0.36)
Controls (140–180)c 44 (0.31) 30 (0.17) 32 (0.18) 28 (0.16) 146 (0.81) 38 (0.21) 45 (0.26)
P valued n.s. <0.01 <0.01 <0.01 n.s. <0.01 n.s.
c.1687C > T Allelesb 152 170 145 145 247 170 149
Cases (14)c 5 (0.36) 7 (0.50) 8 (0.57) 7 (0.50) 12 (0.86) 9 (0.64) 4 (0.29)
Controls (140–180)c 20 (0.14) 30 (0.17) 19 (0.11) 39 (0.22) 146 (0.81) 80 (0.45) 24 (0.14)
P valued n.s. <0.01 <0.01 <0.05 n.s. n.s. n.s.
c.5266dupC Allelesb 154 170 141 151 247 170 153
Cases (18)c 5 (0.28) 7 (0.39) 6 (0.33) 12 (0.67) 17 (0.94) 9 (0.50) 3 (0.17)
Controls (140–180)c 44 (0.31) 30 (0.17) 24 (0.13) 42 (0.24) 146 (0.81) 80 (0.45) 24 (0.14)
P valued n.s. n.s. <0.05 <0.01 n.s. n.s. n.s.
aPhysical map positions on chromosome 17 based on Genome Reference Consortium Human Build 37 (GRCh37) [47] and allele size ranges are indicated for
each locus
bThe most frequent allele of the cases is reported for each locus. Alleles showing statistically significant association (corrected P value < 0.05) are underlined
cTotal number of case and control chromosomes in parentheses. Number of chromosomes carrying the indicated alleles are reported for each locus, along with
the allele frequency in parentheses
dn.s. not significant
eTwo common alleles with similar frequency were observed at this locus
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Ovarian cancer was present in 6/10 families with the
BRCA1 c.676delT (1 to 5 patients per family) and in 4/
18 families with the BRCA2 c.7806-2A > G (1 to 3 pa-
tients per family). Male breast cancer was absent in the
BRCA1 c.676delT pedigrees, but was recorded for the
BRCA2 c.7806-2A > G in 7 out 18 (39 %) families. On
the contrary, male breast cancer was observed in 13 out
80 families (16 %) carrying c.5682C > G and c.8878C > T
or other BRCA2 mutations of our dataset (p = 0.04907).
It is worth of noting that there were 3 males affected by
breast cancer in one family with the c.7806-2A > G mu-
tation (Table 7).
SNaPshot® genotyping strategy
After minor adjustments of primer length for avoiding
some peak overlapping, we were able to simultaneously
detect all 8 single mutated alleles by a single PCR
followed by two multiplex SNaPshot® reactions. Re-
peated experiments carried out on several available
DNA samples gave clear cut and reproducible results.
Examples of the multiplex amplified products and of the
mutated and wild type patterns are illustrated in Fig. 5.
The validity and usefulness of this SNaPshot® assay for
our BRCA pre-screening was evaluated by assaying DNA
samples of patients enrolled for mutation testing, in
Table 4 Frequencies of the most common microsatellite alleles of the BRCA2 region in mutated probands and controls
Markersa
D13S220 D13S267 D13S171 D13S1701 D13S1698 D13S260 D13S290 D13S1246
35169554 34264119 33253912 33144530 32704522 32436758 31429174 31105437
187–203 144–160 226–242 283–311 151–179 154–172 174–192 191–211
c.5682C > G Allelesb 189 156 226 299 155 162 174 201
Cases (10)c 5 (0.5) 3 (0.3) 5 (0.5) 6 (0.6) 6 (0.6) 5 (0.5) 7 (0.7) 4 (0.4)
Controls (142–182)c 59 (0.42) 38 (0.22) 40 (0.22) 51 (0.29) 46 (0.25) 19 (0.11) 105 (0.6) 26 (0.14)
P valued n.s. n.s. n.s. n.s. <0.05 <0.01 n.s. n.s.
c.7806-2A > G Allelesb 199 144 230 299 155 160 174 205
Cases (26)c 10 (0.38) 19 (0.73) 18 (0.69) 16 (0.62) 16 (0.62) 14 (0.54) 20 (0.77) 9 (0.35)
Controls (142–182)c 34 (0.24) 68 (0.40) 73 (0.41) 51 (0.29) 46 (0.25) 28 (0.16) 105 (0.6) 60 (0.33)
P valued n.s. <0.01 <0.02 <0.01 <0.01 <0.01 n.s. n.s.
c.8878C > T Allelesb 189 144 240 287 173 168 174 199
Cases (10)c 4 (0.4) 5 (0.5) 7 (0.7) 5 (0.5) 5 (0.5) 4 (0.4) 8 (0.8) 4 (0.4)
Controls (142–182)c 34 (0.24) 68 (0.4) 61 (0.34) 22 (0.12) 4 (0.02) 28 (0.16) 105 (0.6) 32 (0.18)
P valued n.s. n.s. <0.05 <0.01 <0.01 n.s. n.s. n.s.
aPhysical map positions on chromosome 13 based on Genome Reference Consortium Human Build 37 (GRCh37) [47] and allele size ranges are indicated for
each locus
bThe most frequent allele of the cases is reported for each locus. Alleles showing statistically significant association (corrected P value < 0.05) are underlined
cTotal number of case and control chromosomes in parentheses. Number of chromosomes carrying the indicated alleles are reported for each locus, along with
the allele frequency in parentheses
dn.s. not significant
Fig. 3 Shared haplotype of common mutations: The minimum haplotypes and the size of the microsatellite markers associated with each
mutation are shown. These core haplotypes were found in at least 50 % of the mutated chromosomes, but were absent or rare in the 182
control chromosomes (p < 0.05 in all cases). For each mutation, number of chromosomes with the core haplotype out of the total number of
mutated chromosomes are indicated in brackets
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parallel with standard screening. Among the cases
with North-East Italian geographic origin, 70 pro-
bands were selected based on a BRCApro value > 0.1
and/or a tumor onset before age 60 years. Twelve
new probands were identified in advance as carriers
of one of the common mutations, specifically one
case with BRCA2 c.8878C > T, 2 cases each with
BRCA1 c.116G > A, c.1687C > T, c.5266dupC and
BRCA2 c.7806-2A > G, 3 cases with BRCA1c.181T >
G. All mutations were then confirmed by direct se-
quencing of the multiplex PCR and also of an inde-
pendent single amplified product. BRCA1 c.676delT
and BRCA2 c.5682C > G were not present in this
small series of families.
With DHPLC/Sanger Sequencing/MLPA standard
screening, other less common mutations were detected
in only six additional families (details not reported), thus
confirming an high recurrence of the founder mutations
also in this subset of patient population (12/18).
Discussion
More than a half of the tested breast/ovarian cancer pa-
tients originating from FVG and neighboring geographic
areas of Veneto (Italy) and Istria (Slovenia and Croatia)
were found to be carrier of one of the 8 BRCA1 or
BRCA2 recurrent mutations. Mutations may be observed
repeatedly across unrelated individuals either because
the mutation arises multiple times de novo at hot spot
DNA sites, or because it occurred once in an ancestor
who then transmitted it to the progeny. To demonstrate
the hypothesis of a founder origin, we explored a total of
62 families previously identified to be carriers of the 5
BRCA1 and 3 BRCA2 prevalent mutations in our region
and surrounding territories.
The most recurrent variant was c.7806-2A > G, an in-
tronic mutation of the BRCA2 gene previously known as
IVS16-2A > G, which severely impairs the splicing of
exon 16 [28] and is predicted to remove 57 aminoacids
from the encoded protein (p.Ala2603_Arg2659del). In
Table 5 Haplotype analyses in the BRCA1 c.676delT carrier families
D17S588 D17S806 D17S902 D17S855 (BRCA1)a D17S1328 D17S800 D17S250
BR128 154-156 168-170 149-149 149–153 247–247 170–174 153–159
BR328 154–154 170–172 149–153 147–149 247–247 166–174 149–159
BR384 148–154 170–178 145–149 149–155 247–249 174–174 149–159
BR392 154–159 168–170 149–153 145–149 247–247 174–174 145–155
BR573 154–156 162–176 149–153 147–149 247–251 170–174 149–153
BR613 138–154 170–172 149–153 143–149 247–247 170–174 149–149
BR704 140–154 170–176 145–149 147–149 247–247 170–176 145–155
BR977 154–156 170–174 149–157 149–153 247–247 170–174 151–153
BR1091 148–154 170–170 149–157 149–151 247–247 170–174 151–161
Alleles segregating with the mutation inside each family are represented in bold type. The 149–149–247 shared haplotype is underlined
a D17S855 is located into the BRCA1 locus
Table 6 Haplotype analyses in the BRCA2 c.7806-2A > G carrier families
D13S220 D13S267 D13S171 D13S1701 rs9534262 (BRCA2) D13S1698 D13S260 D13S290 D13S1246
BR6 189-193 144-144 230-240 287-299 C/T 155-159 158-160 174-174 203-203
BR60 189-199 144-144 230-230 299-299 T/T 155-155 158-160 174-174 203-205
BR85 199-199 144-144 230-240 287-299 T/T 159-159 158-158 174-174 203-203
BR195 189-199 144-144 230-240 287-299 T/T 155-159 160-162 174-174 203-205
BR243 189-189 144-156 230-230 295-299 T/T 155-171 160-160 174-188 205-205
BR312 189-199 144-150 230-240 287-299 C/T 155-159 160-166 174-174 201-205
BR434 189-195 144-156 230-240 295-299 T/T 155-155 160-162 174-188 201-203
BR594 189-195 144-150 230-230 295-299 T/T 155-155 156-160 174-188 205-208
BR608 193-195 144-144 230-230 299-307 C/T 155-163 160-170 174-188 201-205
BR953 189-199 144-152 230-230 299-299 T/T 155-159 160-168 174-174 205-205
BR1009 193-199 144-144 226-230 287-299 C/T 155-159 160-168 174-188 201-211
BR1013 189-199 144-156 226-230 299-299 T/T 155-159 160-160 174-174 201-207
CFS864 199-199 144-156 230-240 295-299 C/T 155-155 160-168 174-176 199-207
Alleles segregating with the mutation inside each family are represented in bold type. The 144-230-299 shared haplotype is underlined
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the present series of patients it has been found in 19 un-
related probands, accounting for 8,6 % of all mutated
cases. In the BIC database along with our first recorded
case, only Myriad Genetics appears as depositor of this
mutation (four times). However, this mutation seems to
be as much or more frequent in Slovenia [29, 30] and it
was originally proposed as a Slovenian founder mutation
[31]. In addition, it has also been reported once in an
American pancreatic cancer family [32].
In the present study, we performed haplotype analysis
of 8 microsatellite markers, located in a region of ap-
proximately 7 cM surrounding the BRCA2 gene, in the
13 Italian carrier families all from the FVG region. Our
results demonstrate that the c.7806-2A > G mutation de-
rives from a common ancestor. According to the DMLE
+ 2.2 software, its estimated age is around 94 generations
(average of three estimations), corresponding to approxi-
mately 2350 years ago.
The recurrence in both Italian and Slovenian families
suggests that this mutation has originated only once in
the past, although demonstration that the c.7806-2A > G
chromosomes share the same haplotype has not been
explored in this study. At present, it can only be hypoth-
esized that the c.7806-2A > G could be originated in
FVG and then spread to other near areas where it is
now found at appreciable frequencies, or alternatively,
carriers of this mutation came from a nearby region
(possibly from Slovenia), thus it became frequent in
FVG. It is interesting to note that 5 of the 8 presently
described mutations (BRCA1 c.116G > A, c.181T > G;
c.1687C > T and c.5266dupC, other than BRCA2 c.7806-
2A > G) correspond to highly recurrent mutations also
reported in Slovenia by Krajc et al. [29–31]. This is not
unexpected, if we consider the geographical proximity
between Slovenia and FVG region and the common his-
torical and political heritage over the past centuries.
However, the Slovenian BRCA1 c.844_850dupTCAT-
TAC was not frequent in our dataset, since we found it
only twice, in a North-East Italian family and in one un-
related proband from Poland.
We then chose to investigate BRCA1 c.676delT, which
accounted for almost 5 % of all mutated cases of our data-
set and was not included in the Slovenian recurrent muta-
tion list [30]. Accordingly, we found it 10 times, only in
patients from the FVG area, spread in the four regional
provinces. This mutation, previously defined as c.795delT
in the BIC database, causes frameshift and is predicted to
produce a truncated protein (p.Cys226Valfs*8). Haplotype
analysis of the 9 Italian families with 7 informative micro-
satellite markers, located in a region of approximately
8.8 cM surrounding the BRCA1 gene, demonstrated that
also the c.676delT mutation derives from a common an-
cestor. Its age was estimated as an average of 86 genera-
tions, corresponding to approximately 2150 years ago.
Interestingly, this mutation was recorded 16 times in the
BIC database and it has been recently reported at low fre-
quency in Austria (<2 %), which is another Nation border-
ing on FVG [33].
Unlike other European studies that reported a more
homogeneous distribution of mutations, spread to the
whole national area [4], a high degree of internal hetero-
geneity exists in Italy, due to past isolation of ancient
Fig. 4 Results from DMLE analyses. Posterior probability density of the mutation age for different proportions of mutation-carrying chromosomes
sampled: 0.005, 0.01, 0.015 (blue, green, magenta, respectively). a: Estimates for BRCA1 c.676del. b: Estimates for BRCA2 c.7806 − 2A > G
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populations, genetic drift and different admixture events
[34]. As a consequence, several different BRCA1 and
BRCA2 mutations have been reported that are confined
within restricted geographic areas [9–15]. This seems to
be the case also for some of the recurrent mutations dis-
cussed here, especially BRCA2 c.7806-2A > G and
BRCA1 c.676delT, but also BRCA1 c.116G > A. This lat-
ter is a missense mutation substituting a Cystein in the
ring finger domain of BRCA1 protein (p.Cys39Tyr).
Although it has not yet been classified by BIC and it is
still not listed in the LOVD-IARC database [35], our
segregation data strongly point out in favour of an im-
portant clinical role in conferring breast and ovarian
cancer risk. In our series it appears frequent, but not
limited to Italy, because 8 out of the 11 patients with
this mutation were Italians from the borderlands of FVG
and the other 3 came from Istria. Accordingly, BRCA1
c.116G > A is also described as recurrent in the neigh-
boring western part of Slovenia [30], but rarely reported
by others.
On the basis of literature data and databases of BRCA
variants, the remaining mutations are shared with other
Italian regions, such as the nonsense BRCA2 c.8878C >
T, or have a broader diffusion among Caucasians in Eur-
ope, such as the BRCA1 c.181T > G and c.1687C > T and
BRCA2 c.5682C > G [30, 36–38], or worldwide, such as
BRCA1 c.5266dupC [8, 39].
With regard to the BRCA1 c.5266dupC, we have found
it 15 times. However, in this series of cases only a minor-
ity had a North-East Italian origin, being 9 of the identi-
fied carriers from other non-neighbouring Italian
regions. Despite this, by microsatellite analyses we have
obtained evidence of significant haplotype sharing
among carriers (alleles 151–247 at loci D17S855 and
D17S1328). c.5266dupC, formerly known as 5382insC,
was originally described as a founder mutation in the AJ
population [4]. However, an extended haplotype study
on 14 different population groups demonstrated that all
mutation carriers share a common haplotype that arose
1800 years ago from a single Scandinavian or Russian
founder individual [40]. Thus, it was a common Euro-
pean mutation long before becoming an AJ founder
mutation.
Another useful observation we can gather from our
study concerns the clinical phenotype associated to
BRCA2 c.7806-2A > G. We had already reported its geo-
graphical recurrence in our previous study in which we
also underlined its possible role in predisposition to
male breast cancer [41]. In BRCA2 mutation carriers the
cumulative risk of male breast cancer at age 70 years has
been estimated 6.8 % [42], but evidences for a correl-
ation between the location of the mutation within
BRCA2 gene and risk of male breast cancer are still lack-
ing [43]. The data presented here suggest an association
for c.7806-2A > G, but further studies are necessary for
providing a more precise estimate for a male mutation
carrier of the likelihood of developing breast cancer.
The identification of mutations is efficient and cost-
effective when testing can be limited to a number of
common founder mutations within a defined ethnic
and/or geographical group. However, in our patient
population, genetic testing of high risk families cannot
be restricted to a small number of mutations, since
Table 7 Clinical phenotype of families with founder mutations
Proband Family
Sexa BCbage OCbage F-BCc OCc M-BCc
BRCA1c.676delT
BR128 F 41, 51 - 3 (2) 0 0
BR328 F 23 – 3 (1) 1 0
BR384 F 50, 56 – 3 (1) 1 0
BR392 F 30 – 4 (1) 0 0
BR573 F – 52 1 3 (2) 0
BR613 F – 53 4 (1) 5 (2) 0
BR704 F 29, 31, 31 – 1 (1) 1 0
BR977 F 58 – 4 (1) 0 0
BR1091 F 23, 29 – 2 (1) 0 0
BR1450 F 42 – 2(1) 2 0
BRCA2 c.7806–2A > G
BR6 F 60 – 5 (1) 0 1(1)
BR60 F 45 – 8 (3) 2 (2) 0
BR85 F 41 – 3 (1) 0 0
BR195 M 50 – 5 0 3 (1)
BR243 M 70 – 4 0 1 (1)
BR312 F 47 – 2 (1) 0 1
BR434 F 36 – 4 (3) 3 0
BR594 F 36 – 1 (1) 1 0
BR608 M 67 – 3 (2) 0 1 (1)
BR953 F 39 – 4 (3) 0 1
BR1009 F 36 – 3 (1) 0 0
BR1013d F – – 3 0 0
CFS864 F – 59 1 1 (1) 0
BR1214 F 38 – 7 0 0
BR1341 F 76 – 2 0 0
BR1267 F 45 – 1bil 0 0
BR1548 F 48 – 5 0 0
BR1481 F 48, 69 61 1 0 2
aF female, M male
b Years at diagnosis of tumors in probands, BC breast cancer, OC
ovarian cancer
cNumber of affected cases, including proband; in parentheses the number of
carriers, ascertained or inferred, F–BC female breast cancer, M–BC male
breast cancer
dHealthy young proband, no affected relatives were alive and available for
gene testing
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about half were unique or poorly recurrent. Although
sequencing of the two genes in their entirety is still ne-
cessary, it may be advantageous adopting the SNaPshot®
assay we have developed for rapidly pre-screening the 8-
mutation panel. Customized BRCA1 and BRCA2 SNaP-
shot® tests have been previously implemented also by
other groups for assaying their own most common mu-
tations [44, 45].
Target re-sequencing on a Next Generation Sequen-
cing instrument is now available in our laboratory to
overcome the increasing demand of rapid testing,
often for orienting surgical or therapeutic decisions.
However, the proposed genotyping strategy is still an
useful option for less equipped laboratories and could
also be adopted as a cost-effective approach for
testing larger populations of patients in North-East of
Italy.
Conclusions
Five BRCA1 and 3 BRCA2 recurrent mutations account for
more than half of the patients with proven hereditary
breast/ovarian cancer originating from FVG and neighbor-
ing geographic areas. Proofs of common ancestry has been
obtained for all eight mutations, also providing evidence
that BRCA1 c.676delT and BRCA2 c.7806-2A >G arose
around 90 generations ago. Rapid genotyping of these
highly recurrent mutations could be offered to a larger
number of breast and/or ovarian cancer patients with
North-East Italian origin, irrespective of the established
diagnostic criteria for hereditary tumors.
Fig. 5 SNaPshot® analyses. a: Example of the multiplex and single amplified products; lane 1, 50 bp marker; lane 2 and 3, multiplex PCR of two
different samples; lane 4, negative control of multiplex PCR; lane 5–12: single PCR products, in the order BRCA1 exon 3, 5, 11–1, 11–3, 20 and
BRCA2 exon 17, 11-M, 22. b and c: Representative electropherograms of wild-type and mutated SNaPshot® reactions of BRCA1 (B) and BRCA2 (C).
The nucleotides added by primer extension are shown in blue (G), black (C), red (T) and green (A);*, extension performed with an
antisense primer
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